Reviewers: Charanjeet Singh, M.D. (see Reviewers page)
Revised: 23 May 2012, last major update May 2012
Copyright: (c) 2003-2012, PathologyOutlines.com, Inc.
● This discussion excludes carcinoid tumors and small cell carcinoma
● Rare; highly aggressive with nodal metastases (Am J Surg Pathol 1990;14:1010, Dis Colon Rectum 2004;47:163)
● Often high stage at diagnosis (Dis Colon Rectum 2004;47:163)
● Mixed neuroendocrine carcinoma-adenocarcinoma also occurs (Virchows Arch 2006;448:644)
● Organoid appearance, larger cells than small cell carcinoma, marked nuclear pleomorphism, large irregular hyperchromatic nuclei with prominent nucleoli, frequent mitotic activity and tumor necrosis
Concurrent large cell neuroendocrine carcinoma (ulcerative fungating mass) and adenocarcinoma (polypoid mass)
Ampulla of Vater
Trabecular pattern with mitotic activity
● Cytokeratin, usually EMA, NSE, chromogranin and synaptophysin
● c-kit/CD117 in 23% but not associated with activating mutations (Am J Surg Pathol 2003;27:1551)
● Focal neuroendocrine cells in adenocarcinoma: more common (Arch Pathol Lab Med 1998;122:912)
● Glandular-neuroendocrine mixed tumor: either composite or collision tumors (Am J Surg Pathol 2011;35:413)
● Korean J Gastroenterol 2006;48:97
End of Colon tumor > Carcinoma > Neuroendocrine carcinoma
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.
All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).